Efficacy and Safety of Immunization With Pneumococcal Polysaccharide Vaccine in Children With Juvenile Idiopathic Arthritis: Preliminary Results of a Prospective Open-Label Study

Алексеева, Е. И.; Солошенко, М. А.; Дворяковская, Т. М.; Ломакина, О. Л.; Денисова, Р. В.; Исаева, К. Б.; Карасёва, А. В.

doi:10.15690/vsp.v16i2.1715

Cited by 1 publication

(2 citation statements)

References 6 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccine coverage against pneumococcus was 5% in the Australian pediatric IBD cohort, 18.6% in 430 pediatric IBD patients, from a multicentre study, and 50.3% in JIA patients from Switzerland without differences irrespective of immune-suppressive therapy[ 33 , 47 , 48 ]. In the study of pneumococcal and anti-Hib vaccination of non-systemic and systemic JIA patients was shown the decreasing number of episodes of acute respiratory infections different etiology[ 49 ]. No differences in response related to treatment and disease activity stage were observed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination coverage in children with juvenile idiopathic arthritis, inflammatory bowel diseases, and healthy peers: Cross-sectional electronic survey data

MAKAROVA¹,

Khabirova²,

Volkova³

et al. 2023

World J Clin Pediatr

View full text Add to dashboard Cite

BACKGROUND Patients with immune-mediated diseases, such as juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD) are at increased risk of developing infections, due to disease-related immune dysfunction and applying of immunosuppressive drugs. AIM To evaluate vaccine coverage in patients with IBD and JIA, and compare it with healthy children. METHODS In the cross-sectional study we included the data from a questionnaire survey of 190 Legal representatives of children with JIA ( n = 81), IBD ( n = 51), and healthy children (HC, n = 58). An electronic online questionnaire was created for the survey. RESULTS There were female predominance in JIA patients and younger onset age. Parents of JIA had higher education levels. Employment level and family status were similar in the three studied groups. Patients with JIA and IBD had lower vaccine coverage, without parental rejection of vaccinations in IBD, compare to JIA and healthy controls. The main reason for incomplete vaccination was medical conditions in IBD and JIA. IBD patients had a lower rate of normal vaccine-associated reactions compared to JIA and HC. The encouraging role of physicians for vaccinations was the lowest in JIA patients. IBD patients had more possibilities to check antibodies before immune-suppressive therapy and had more supplementary vaccinations compared to JIA and HC. CONCLUSION JIA and IBD patients had lower vaccine coverage compared to HC. Physicians' encouragement of vaccination and the impossibility of discus about future vaccinations and their outcomes seemed the main factors for patients with immune-mediated diseases, influencing vaccine coverage. Further investigations are required to understand the reasons for incomplete vaccinations and improve vaccine coverage in both groups, especially in rheumatic disease patients. The approaches that stimulate vaccination in healthy children are not always optimal in children with immune-mediated diseases. It is necessary to provide personalized vaccine-encouraging strategies for parents of chronically ill children with the following validation of these technics.

show abstract

Section: Discussionmentioning

confidence: 99%

“…No differences in response related to treatment and disease activity stage were observed. The vaccination against both infections was safe and not associated with following short-term flares[ 49 , 50 ].…”

Section: Discussionmentioning

confidence: 99%